Article ID Journal Published Year Pages File Type
6182827 Gynecologic Oncology 2014 7 Pages PDF
Abstract
Addition of bevacizumab, by in large, is cost-ineffective. It can become cost-effective with the ICON-7 protocol, in patients at high risk of progression using biosimilar bevacizumab.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Obstetrics, Gynecology and Women's Health
Preview
Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer
Authors
, ,